NASDAQ:PRAX Praxis Precision Medicines (PRAX) Stock Price, News & Analysis → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Free PRAX Stock Alerts $61.02 +1.82 (+3.07%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$56.50▼$64.7050-Day Range$36.98▼$62.1852-Week Range$11.85▼$67.21Volume1.78 million shsAverage Volume211,087 shsMarket Capitalization$807.90 millionP/E RatioN/ADividend YieldN/APrice Target$103.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Praxis Precision Medicines alerts: Email Address Praxis Precision Medicines MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside68.8% Upside$103.00 Price TargetShort InterestHealthy3.25% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.45Based on 24 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($8.78) to ($9.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.35 out of 5 starsMedical Sector558th out of 938 stocksPharmaceutical Preparations Industry249th out of 417 stocks 3.4 Analyst's Opinion Consensus RatingPraxis Precision Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $103.00, Praxis Precision Medicines has a forecasted upside of 68.8% from its current price of $61.02.Amount of Analyst CoveragePraxis Precision Medicines has only been the subject of 3 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.25% of the float of Praxis Precision Medicines has been sold short.Short Interest Ratio / Days to CoverPraxis Precision Medicines has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Praxis Precision Medicines has recently decreased by 1.30%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPraxis Precision Medicines does not currently pay a dividend.Dividend GrowthPraxis Precision Medicines does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRAX. Previous Next 3.0 News and Social Media Coverage News SentimentPraxis Precision Medicines has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Praxis Precision Medicines this week, compared to 2 articles on an average week.Search Interest11 people have searched for PRAX on MarketBeat in the last 30 days. This is an increase of 22% compared to the previous 30 days.MarketBeat Follows7 people have added Praxis Precision Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Praxis Precision Medicines insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.70% of the stock of Praxis Precision Medicines is held by insiders.Percentage Held by Institutions67.84% of the stock of Praxis Precision Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Praxis Precision Medicines are expected to decrease in the coming year, from ($8.78) to ($9.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Praxis Precision Medicines is -2.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Praxis Precision Medicines is -2.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPraxis Precision Medicines has a P/B Ratio of 7.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Praxis Precision Medicines Stock (NASDAQ:PRAX)Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Read More PRAX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRAX Stock News HeadlinesMarch 28, 2024 | markets.businessinsider.comPraxis Precision Medicines Announces Pricing Of Underwritten Public OfferingMarch 28, 2024 | americanbankingnews.comPraxis Precision Medicines (NASDAQ:PRAX) Sets New 52-Week High on Analyst UpgradeMarch 29, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 28, 2024 | globenewswire.comPraxis Precision Medicines, Inc. Announces Pricing of $200 Million Public OfferingMarch 27, 2024 | globenewswire.comPraxis Precision Medicines, Inc. Announces Proposed Public OfferingMarch 27, 2024 | americanbankingnews.comPraxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $128.00 at Jefferies Financial GroupMarch 27, 2024 | americanbankingnews.comPraxis Precision Medicines' (PRAX) Buy Rating Reaffirmed at HC WainwrightMarch 26, 2024 | msn.comPraxis gains after mid-stage data for epilepsy candidateMarch 29, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 26, 2024 | markets.businessinsider.comPraxis Precision Medicines Reports Positive Results From PRAX-628 Study - Quick FactsMarch 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Praxis Precision Medicines’ PRAX-628 Based on Strong Clinical Trial Outcomes and Market PotentialMarch 26, 2024 | msn.comWhy Praxis Precision Medicines Stock Is Trading Higher TuesdayMarch 26, 2024 | finance.yahoo.comTop 1% Biotech, Praxis, Releases 'Fireworks' And Catapults To Year-HighMarch 26, 2024 | seekingalpha.comPraxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory FilingMarch 26, 2024 | globenewswire.comPraxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated PatientsMarch 25, 2024 | globenewswire.comPraxis Precision Medicines to Host PRAX-628 Program UpdateMarch 25, 2024 | finance.yahoo.comA Look At The Intrinsic Value Of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)March 24, 2024 | americanbankingnews.comPraxis Precision Medicines (NASDAQ:PRAX) Shares Gap Up to $52.41March 20, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Clene (CLNN) and Jazz Pharmaceuticals (JAZZ)March 19, 2024 | ca.finance.yahoo.comPRAX Apr 2024 60.000 callMarch 16, 2024 | finance.yahoo.comPRAX May 2024 22.500 callMarch 15, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Allakos (ALLK), Century Therapeutics (IPSC)March 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Praxis Precision Medicines Amidst Promising Pipeline and Financial StabilityMarch 7, 2024 | finance.yahoo.comPraxis Precision Medicines Inc (PRAX) Reports Full-Year 2023 Financial Results and Corporate UpdatesMarch 7, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), InMode (INMD) and Teladoc (TDOC)March 6, 2024 | msn.comPraxis Precision Medicines files for $750M mixed shelf offeringMarch 5, 2024 | globenewswire.comPraxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial ResultsSee More Headlines Receive PRAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Praxis Precision Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today3/29/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PRAX CUSIPN/A CIK1689548 Webwww.praxismedicines.com Phone617-300-8460FaxN/AEmployees82Year FoundedN/APrice Target and Rating Average Stock Price Target$103.00 High Stock Price Target$150.00 Low Stock Price Target$29.00 Potential Upside/Downside+68.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($23.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-123,280,000.00 Net Margins-5,037.88% Pretax Margin-5,037.88% Return on Equity-151.02% Return on Assets-115.60% Debt Debt-to-Equity RatioN/A Current Ratio5.39 Quick Ratio5.39 Sales & Book Value Annual Sales$2.45 million Price / Sales329.76 Cash FlowN/A Price / Cash FlowN/A Book Value$7.92 per share Price / Book7.70Miscellaneous Outstanding Shares13,240,000Free Float12,881,000Market Cap$807.90 million OptionableOptionable Beta2.85 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Marcio Silva De'Souza M.B.A. (Age 44)President, CEO & Director Comp: $1.18MMr. Timothy Edwin Kelly (Age 50)CFO & Treasurer Comp: $691.58kMr. Alex Nemiroff J.D. (Age 44)General Counsel & Secretary Comp: $577.34kDr. Steven Petrou B.Sc. (Hons.)Ph.D., Co-Founder & Chief Scientific OfficerLauren MastrocolaVP of Finance & Principal Accounting OfficerDr. Karl Hansen Ph.D.Chief Technical Operations OfficerAlex KaneVP of Investor Relations & Corporate CommunicationsMs. Kelly McCueChief People OfficerMs. Alyssa J. S. Wyant (Age 49)Chief Regulatory & Quality Officer Ms. Megan T. Sniecinski (Age 42)Chief Business Officer More ExecutivesKey CompetitorsEvolusNASDAQ:EOLSTango TherapeuticsNASDAQ:TNGXTyra BiosciencesNASDAQ:TYRAIntercept PharmaceuticalsNASDAQ:ICPTPliant TherapeuticsNASDAQ:PLRXView All CompetitorsInsiders & InstitutionsKingdon Capital Management L.L.C.Sold 4,853,335 shares on 3/18/2024Ownership: 2.618%Vanguard Group Inc.Sold 5,193,176 shares on 3/11/2024Ownership: 4.220%Bridgeway Capital Management LLCSold 180,548 shares on 2/15/2024Ownership: 0.241%Barclays PLCBought 9,245 shares on 2/15/2024Ownership: 0.105%Citadel Advisors LLCBought 66 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions PRAX Stock Analysis - Frequently Asked Questions Should I buy or sell Praxis Precision Medicines stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Praxis Precision Medicines in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PRAX shares. View PRAX analyst ratings or view top-rated stocks. What is Praxis Precision Medicines' stock price target for 2024? 4 Wall Street analysts have issued 1 year target prices for Praxis Precision Medicines' stock. Their PRAX share price targets range from $29.00 to $150.00. On average, they expect the company's share price to reach $103.00 in the next year. This suggests a possible upside of 68.8% from the stock's current price. View analysts price targets for PRAX or view top-rated stocks among Wall Street analysts. How have PRAX shares performed in 2024? Praxis Precision Medicines' stock was trading at $22.28 on January 1st, 2024. Since then, PRAX stock has increased by 173.9% and is now trading at $61.02. View the best growth stocks for 2024 here. When is Praxis Precision Medicines' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our PRAX earnings forecast. How were Praxis Precision Medicines' earnings last quarter? Praxis Precision Medicines, Inc. (NASDAQ:PRAX) announced its earnings results on Tuesday, March, 5th. The company reported ($2.97) EPS for the quarter, beating analysts' consensus estimates of ($3.05) by $0.08. The business earned $0.52 million during the quarter, compared to analyst estimates of $0.30 million. Praxis Precision Medicines had a negative net margin of 5,037.88% and a negative trailing twelve-month return on equity of 151.02%. When did Praxis Precision Medicines' stock split? Shares of Praxis Precision Medicines reverse split on Wednesday, November 29th 2023. The 1-15 reverse split was announced on Wednesday, November 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Praxis Precision Medicines IPO? Praxis Precision Medicines (PRAX) raised $126 million in an initial public offering on Friday, October 16th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Cowen, Evercore ISI, Piper Sandler and Wedbush PacGrow acted as the underwriters for the IPO and Blackstone Capital Markets was co-manager. Who are Praxis Precision Medicines' major shareholders? Praxis Precision Medicines' stock is owned by many different institutional and retail investors. Top institutional investors include Verition Fund Management LLC (8.00%), Point72 Asset Management L.P. (7.87%), PFM Health Sciences LP (7.47%), Vanguard Group Inc. (4.22%), Vanguard Group Inc. (4.22%) and Kingdon Capital Management L.L.C. (2.62%). Insiders that own company stock include Alex Nemiroff, Dean J Mitchell, Jill Desimone, Lauren Mastrocola, Marcio Souza, Parallel Master Fund LP Bsof and Timothy Edwin Kelly. View institutional ownership trends. How do I buy shares of Praxis Precision Medicines? Shares of PRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRAX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.